TLDR
- RYTM launches IMCIVREE for rare acquired hypothalamic obesity patients.
- Phase 3 trial shows -15.8% BMI reduction vs placebo for setmelanotide.
- FDA approval covers adults and children 4+ with hypothalamic obesity.
- IMCIVREE now available in the U.S. with patient support program.
- Rhythm strengthens MC4R therapy portfolio for rare obesity disorders.
Rhythm Pharmaceuticals (RYTM) stock declined to $87.45, down 3.17%, following FDA approval of IMCIVREE® for acquired hypothalamic obesity. The company now holds the first FDA-approved treatment for this rare condition. The development significantly expands the commercial potential of setmelanotide in the U.S. market.
Rhythm Pharmaceuticals, Inc., RYTM
The new FDA label covers adults and children aged four and older living with acquired hypothalamic obesity. The condition causes accelerated, sustained weight gain due to hypothalamic injury or dysfunction. IMCIVREE addresses the underlying biology, offering long-term weight reduction for affected patients.
Rhythm Pharmaceuticals anticipates approximately 10,000 patients in the U.S. could benefit from this new indication. The approval strengthens the company’s portfolio of MC4R pathway-targeted therapies. It builds on prior approvals for syndromic and monogenic obesity disorders in adults and children.
FDA Approval Backed by Positive Phase 3 Data
The approval follows results from the pivotal Phase 3 TRANSCEND trial of setmelanotide. Participants on therapy achieved a -15.8% reduction in BMI compared with a +2.6% increase for placebo patients. The placebo-adjusted reduction reached -18.4%, demonstrating a statistically significant clinical effect.
Trial data showed setmelanotide was generally well tolerated among participants. Common adverse effects included skin hyperpigmentation, nausea, vomiting, and headache. The safety profile supports long-term use for patients living with acquired hypothalamic obesity.
The global study enrolled 142 patients, including adults and children, to assess efficacy and tolerability. The trial endpoints focused on BMI reduction and hunger control over 52 weeks. Results confirmed the therapy’s targeted effect on the MC4R pathway and obesity management.
Commercial and Patient Access Initiatives
Rhythm Pharmaceuticals will make IMCIVREE available immediately for patients in the U.S. The company also provides the Rhythm InTune support program for patient education and treatment assistance. The program includes insurance navigation, injection guidance, and ongoing therapy support for patients and providers.
The expanded approval positions Rhythm as the only company offering a targeted treatment for acquired hypothalamic obesity. It strengthens the company’s role in rare disease therapy and chronic obesity management. The development supports the company’s strategic focus on high-unmet-need populations and specialized care pathways.
The approval complements prior U.S. and European indications for Bardet-Biedl syndrome, POMC, PCSK1, and LEPR deficiency. By addressing these rare conditions, Rhythm continues to build expertise in MC4R pathway diseases. The FDA decision enhances market opportunities while providing patients previously without options a viable treatment pathway.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
